Editorial: Strategies in the drug discovery and development for leishmaniasis: immunomodulators, natural products, synthetic compounds, and drug repositioning.

Autor: de Almeida TF; Laboratory of Physiopathology, Biosciences Applied to Health Department, Institute of Medical Sciences, Multidisciplinary Center of Federal University of Rio de Janeiro, Macaé, Brazil., Cunha-Junior EF; Laboratory of Immunoparasitology, Institute of Pharmaceutical Sciences, Multidisciplinary Center of Federal University of Rio de Janeiro, Macaé, Brazil., Wanderley JLM; Laboratory of Immunoparasitology, Biosciences Applied to Health Department, Institute of Medical Sciences, Multidisciplinary Center of Federal University of Rio de Janeiro, Macaé, Brazil., Pacheco JDS; Drug Discovery Unit, Department of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, United Kingdom., Pinto-da-Silva LH; Institute of Veterinary, Department of Veterinary Microbiology and Immunology, Seropédica, RJ, Brazil., Andrade-Neto VV; St Michael Hospital, Li ka Shing Knowledge Institute, Toronto, ON, Canada., Chaves SP; Laboratory of Immunoparasitology, Biosciences Applied to Health Department, Institute of Medical Sciences, Multidisciplinary Center of Federal University of Rio de Janeiro, Macaé, Brazil.
Jazyk: angličtina
Zdroj: Frontiers in cellular and infection microbiology [Front Cell Infect Microbiol] 2024 Mar 13; Vol. 14, pp. 1384244. Date of Electronic Publication: 2024 Mar 13 (Print Publication: 2024).
DOI: 10.3389/fcimb.2024.1384244
Abstrakt: Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Databáze: MEDLINE